3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
38
Neoplasm Metastasis
7
Neoplasms by Site
3
Neoplasms
3
Breast Diseases
3
Hereditary Sensory and Autonomic Neuropathies
2
Endometrial Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Anatomic Stage II Breast Cancer AJCC v8
2
Uterine Cervical Neoplasms
1
Unilateral Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumors
1
Sarcoma
1
Recurrence
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Melanoma
1
Lung Neoplasms
1
Locoregional Recurrence
1
Locally Advanced (Inoperable) or Metastatic Breast Cancer
1
Liposarcoma
1
Leiomyosarcoma
1
Head and Neck Neoplasms
1
HR+/HER2- Breast Cancer
1
HER2 Negative Breast Cancer Not Immediately Operated
1
HER2 Negative Breast Cancer
1
Glioma
1
Glioblastoma
1
Interventions
pembrolizumab
12
Cisplatin
11
Specimen Handling
9
Bevacizumab
8
Brachytherapy
6
Platinum
5
Paclitaxel
5
Nivolumab
5
Magnetic Resonance Spectroscopy
5
Human Papillomavirus DNA Tests
5
Colposcopy
5
Carboplatin
5
atezolizumab
4
Gemcitabine
4
Fulvestrant
4
Surveys and Questionnaires
3
Radiotherapy
3
Radiation Dose Hypofractionation
3
Radiation
3
Drug Therapy
3
Blood Specimen Collection
3
1,2-diaminocyclohexaneplatinum II citrate
3
tisotumab vedotin
2
palbociclib
2
lenvatinib
2
Topotecan
2
Restraint, Physical
2
Radiotherapy, Intensity-Modulated
2
Pemetrexed
2
Magnetic Resonance Imaging
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Uterine Cervical Neoplasms
×
ribociclib
×
90 days
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled